Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01224665 · ClinicalTrials.gov registry record · NA
S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
A NA study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- NA
- Development phase
- 658
- Enrollment target
NCT01224665: Completed NA study, sponsored by SWOG Cancer Research Network.
NCT01224665 is a NA study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 658 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01224665, a NA study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 658 participants
- Enrollment target
Study Summary
RATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with invasive bladder cancer. It is not yet known whether extended pelvic lymphadenectomy is more effective than standard pelvic lymphadenectomy during surgery. PURPOSE: This randomized phase II trial is studying standard pelvic lymphadenectomy to see how well it works compared to extended pelvic lymphadenectomy in treating patients undergoing surgery for invasive bladder cancer.
Primary Outcome
Comparing 5-year disease-free survival (DFS) in participants undergoing radical cystectomy for muscle-invasive urothelial carcinoma of the bladder (UCB) treated with radical cystectomy and extended pelvic lymph node dissection (PLND) compared to radical cystectomy and standard pelvic lymphadenectomy. Disease-free survival is defined as the time from the date of randomization to date of first documentation of relapse/recurrence or death due to any cause. Participants last known to be alive withou
Interventions
- PROCEDURE therapeutic conventional surgery
- PROCEDURE therapeutic standard lymphadenectomy
- PROCEDURE therapeutic extended lymphadenectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 658 participants |
| Start Date | 2011-11-25 |
| Est. Completion | 2024-05 |
| Phase | NA |
What the finished NCT01224665 record still lists
NCT01224665 is an interventional study that assigns participants to a tested intervention. The registered 658 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 3 interventions - of which therapeutic conventional surgery is the first listed.
NCT01224665 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01224665 about?
NCT01224665 is a clinical study titled "S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer". RATIONALE: Lymphadenectomy may remove tumor cells that have spread to nearby lymph nodes in patients with invasive bladder cancer. It is not yet known whether extended pelvic lymphadenectomy is more effective than standard pelvic lymphadenectomy during surgery. PURPOSE: This randomized phase II tri...
What is the current status of trial NCT01224665?
This trial is currently completed. It is a NA study. The enrollment target is 658 participants. The study started on 2011-11-25. Estimated completion is 2024-05.
What interventions are being tested in trial NCT01224665?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), therapeutic standard lymphadenectomy (PROCEDURE), therapeutic extended lymphadenectomy (PROCEDURE).
Who is sponsoring clinical trial NCT01224665?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01224665's enrollment target sits among peer trials
658 156th of 2000 higher than 1,845 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07216742 · 659 participants · Phase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI